In January 2023, positive data was presented from the ongoing clinical Phase I/IIa study of BI-1206 in combination with rituximab for the treatment of non-Hodgkin’s lymphoma (NHL). Data suggest ...

ECHELON-3 (NCT04404283) principal investigator Craig A. Portell, MD, speaks to the significance of this triplet approval from ...

Discover how innovative lymphoma treatments are transforming patient outcomes, from targeted therapies to immunotherapy ...

ADCs in Preclinical Development for the Treatment of B-cell Malignancies With the evolving clinical data demonstrating the feasibility of the ADC platform in hematologic malignancies, the ...

In addition, we were pleased to see Phase 2 IIT indolent lymphoma data presented at ... single-agent drugs with complementary mechanisms of action will yield additive or synergistic efficacy ...

First, we have reported a 39% objective response rate from our Phase 1 trial of soquelitinib in patients with relapsed T cell lymphoma ... highlights its mechanism of action, skewing ...

It is said to be the first antidepressant with a new mechanism ... combination with rituximab and bendamustine as a second-line treatment for adults with diffuse large B-cell lymphoma (DLBCL ...

LP-284 continued enrollment in its Phase 1A, first-in-human clinical trial for relapsed/refractory non-Hodgkin’s lymphoma and solid tumors ... Lantern believes that this mechanism can be redirected as ...

A prospective, single-arm, phase II study (41) conducted at Peking Union Medical College Hospital in China included 9 patients with IVLBCL, who received zanubrutinib combined with R-CHOP (rituximab ..

1,2 Do you think that's because of the mechanism of action ... superiority of zanubrutinib vs bendamustine + rituximab in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN ...